INmune Bio(NASDAQ) INMB

INmune Bio develops drugs that help the body’s immune system fight diseases. Its main products aim to treat cancer and Alzheimer’s disease. These therapies target patients with few treatment options, such as those with advanced cancer or memory loss.

What’s in the INmune Toolbox?

DN-TNF Platform: Drugs that block harmful inflammation without suppressing the whole immune system. Generated no revenue (GAAP) in Q3 2024.

XPro1595: A treatment in trials for Alzheimer’s disease and depression. 0% of revenue (GAAP) for Q3 2024.

INB03: Immunotherapy for blood cancers and solid tumors, including drug-resistant breast cancer. 0% of revenue (GAAP) for Q3 2024.

INKmune: Therapy that boosts natural killer cells to fight cancer, focused on leukemia and prostate cancer. 0% of revenue (GAAP) for Q3 2024.

CORDstrom: Sells stem cells for research and clinical trials. 100% of revenue for the nine months ended September 30, 2024.

Growth Moves: INmune’s Expansion Playbook

XPro1595 is currently in a Phase II trial for Alzheimer’s disease.

Started Phase I/II trial for INKmune in prostate cancer in 2023; expanded to new patient groups in 2024.

Formed licensing deals with Xencor, Immune Ventures, and the University of Pittsburgh.

Entered clinical trials in Australia, UK, Canada, France, Germany, Spain, Poland, Czech Republic, and Slovakia since 2023.

Why INmune Is a Bit Different

INmune focuses on selective immune therapies that avoid broad immune suppression. Its approach aims to target disease while reducing side effects. The company runs international trials and uses tax incentives to lower research costs.

Five Things You Need to Know

Revenue for nine months ended September 30, 2024: $14,000, all from stem cell sales.

Net loss (GAAP) for the first nine months of 2024 was $32.9 million, up from $21.6 million in the same period of 2023.

Cash and equivalents (GAAP) totaled $33.6 million as of Q3 2024.

All main drug candidates are in clinical trials, not yet approved for sale.

Management warns current cash may not last one year without new funding.

Bottom Line

INmune Bio is a small biotech focused on immune-based therapies for hard-to-treat diseases. The company remains in early development, with all revenue from research products and ongoing funding needs.